The global DNA and gene cloning services market size was estimated at around USD 2.54 billion in 2023 and it is projected to hit around USD 10.68 billion by 2033, growing at a CAGR of 15.45% from 2024 to 2033.
The DNA and gene cloning services market has experienced significant growth driven by advancements in biotechnology, increasing demand for personalized medicine, and the rise in genetic research. These services are crucial for various applications, including drug development, gene therapy, and agricultural biotechnology
The DNA and gene cloning services market is propelled by an advancements in biotechnology, particularly in gene-editing technologies like CRISPR-Cas9, have significantly enhanced the precision and efficiency of cloning processes, driving market expansion. The rising demand for personalized medicine, which necessitates precise genetic modifications, is another critical driver. Additionally, the increasing volume of genetic research, supported by substantial investments from both public and private sectors, contributes to the market's growth. The expanding applications of DNA and gene cloning in pharmaceuticals, agriculture, and academic research further fuel demand. Moreover, the emergence of automated cloning systems has improved throughput and reduced operational costs, making these services more accessible and attractive to a broader range of end-users.
North America dominated the DNA and gene cloning services market, accounting for a 41% revenue share in 2023. This growth is attributed to advanced healthcare infrastructure, a strong presence of leading biotechnology firms, and significant funding for recombinant DNA (rDNA) technology research. The increasing demand for personalized medicine and the rising prevalence of chronic and hereditary diseases are expected to further drive the market.
| Attribute | North America |
| Market Value | USD 1.04 Billion |
| Growth Rate | 15.56% CAGR |
| Projected Value | USD 4.37 Billion |
The U.S. DNA and gene cloning services market size was estimated at USD 0.72 billion in 2023 and it is expected to surpass around USD 3.06 billion by 2033, poised to grow at a CAGR of 15.56% from 2024 to 2033.
The U.S. DNA and gene cloning services market is anticipated to grow from 2024 to 2033 due to increasing government funding, a focus on targeted treatments, regenerative medicine, and the rising prevalence of diseases. Growing research in drug discovery and personalized medicine, along with the strong presence of biotechnology and biopharmaceutical companies, is expected to fuel market growth.
Europe
The Europe DNA and gene cloning services market is expected to grow over the forecast period, driven by the strong presence of biopharmaceutical companies producing recombinant vaccines and biologics. Increasing research and development activities, collaborations between pharmaceutical companies and research institutions, and a growing demand for novel antibiotics and enzymes further propel market growth. In the UK, the market is expected to grow at a CAGR of 17.2% due to the rising prevalence of cancer and growing demand for targeted therapies. Government laws regarding genetically modified crops are also likely to boost the market. For example, in March 2023, the Government of England legalized the commercial production of gene-edited food, enhancing agricultural outcomes and food production through rDNA technology.
Asia Pacific
The Asia Pacific DNA and gene cloning services market is expected to experience rapid growth, with a projected CAGR of 16.78% from 2024 to 2033. This growth is attributed to the rising prevalence of chronic diseases, increasing research activities, advancements in genetic engineering, rising adoption of gene therapies, and a strong presence of biotechnology and biopharmaceutical companies. In China, the market is anticipated to grow due to increasing investments in healthcare innovation and research. The country's focus on advancing biotechnology and immunotherapy, coupled with rising awareness of personalized medicine, is driving market expansion.
The gene synthesis services segment dominated the market with the largest revenue share of 41% in 2023. Gene synthesis services are vital in synthetic biology, enabling the creation of custom DNA sequences without a template. This allows researchers to design and construct genes with specific traits tailored to their research needs, optimizing gene expression levels through codon optimization. Companies provide gene synthesis services, including DNA synthesis, cloning, recombinant expression projects, and downstream services such as sub-cloning, mutagenesis, and plasmid preparation.
The custom cloning services segment is expected to grow at the fastest CAGR of 16.52% from 2024 to 2033. Custom cloning services offer benefits like saving time, ensuring accuracy, and providing access to specialized vectors and techniques not readily available in typical laboratory settings. These services include gene synthesis & mutagenesis, molecular cloning, and shRNA & RNAi cloning services.
The DNA sequencing segment held the largest revenue share of 40% in 2023 and is anticipated to grow at the fastest CAGR during the forecast period. Gene cloning is essential for DNA sequencing as it allows scientists to create copies of specific genes for further analysis. By inserting genes into vectors like plasmids or viral vectors and introducing them into host cells for replication, researchers can accurately determine the nucleotide sequences. This process is crucial for understanding the genetic makeup and function of genes.
The mutagenesis segment is also expected to see significant growth from 2024 to 2033. Gene cloning is critical in mutagenesis, allowing researchers to introduce specific mutations into genes for various studies and applications. Combining gene cloning and mutagenesis enables the creation of customized genetic constructs for applications in molecular biology, biotechnology, and genetics, revolutionizing genetic engineering and expanding possibilities for gene function and regulation studies.
The academic and research institutes segment led the market with a revenue share of 39% in 2023. Research institutes collaborate with service providers to accelerate research programs requiring gene fragment characterization and synthesis. For example, in January 2024, GSK and Elegen Corporation collaborated to develop cell-free DNA-based vaccines and medicines. DNA and gene cloning services bridge basic research with clinical applications in translational studies, helping scientists develop potential therapies, diagnostic tools, or biomarkers.
The CROs & CMOs segment is projected to grow at the fastest CAGR of 16.57% from 2024 to 2033. The high number of contract research organizations (CROs) providing gene synthesis services is expected to boost revenue in the region. Companies like GenScript have a significant presence across North America, offering a broad range of services, including antibody drug development and custom gene synthesis.
By Service
By Application
By End use
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Service Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on DNA and Gene Cloning Services Market
5.1. COVID-19 Landscape: DNA and Gene Cloning Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global DNA and Gene Cloning Services Market, By Service
8.1. DNA and Gene Cloning Services Market, by Service, 2024-2033
8.1.1 Gene Synthesis
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Custom Cloning
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Sub-cloning
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global DNA and Gene Cloning Services Market, By Application
9.1. DNA and Gene Cloning Services Market, by Application, 2024-2033
9.1.1. DNA Sequencing
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Mutagenesis
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Genotyping
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global DNA and Gene Cloning Services Market, By End use
10.1. DNA and Gene Cloning Services Market, by End use, 2024-2033
10.1.1. Academic & Research Institutes
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Pharmaceutical & Biotechnology Companies
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. CMOs & CROs
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global DNA and Gene Cloning Services Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Service (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by End use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.3. Market Revenue and Forecast, by End use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.6.3. Market Revenue and Forecast, by End use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.7.3. Market Revenue and Forecast, by End use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.3. Market Revenue and Forecast, by End use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.6.3. Market Revenue and Forecast, by End use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.7.3. Market Revenue and Forecast, by End use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.6.3. Market Revenue and Forecast, by End use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.7.3. Market Revenue and Forecast, by End use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.3. Market Revenue and Forecast, by End use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.4.3. Market Revenue and Forecast, by End use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.5.3. Market Revenue and Forecast, by End use (2021-2033)
Chapter 12. Company Profiles
12.1. Sezzle.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sezzle.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sezzle.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sezzle.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sezzle.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Sezzle
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sezzle.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sezzle
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sezzle.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sezzle
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers